CoronaryAtlas logo
CoronaryAtlas
Apolipoprotein A-I
Pathway / Lipid retention & oxidation

Apolipoprotein A-I

APOA1protein

ApoA-I is the major HDL component mediating reverse cholesterol transport and endothelial protective effects; reduced levels indicate atherosclerotic burden.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleHDL apolipoprotein; reverse cholesterol transport; atheroprotective; altered in ACS.
Also acts inSystemic / off-pathway
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000118137

Type I vs non-Type I discrimination

ScoresIndeterminate
R — rupture / Type-I
67
C — non-Type-I
44
A — assay feasibility
84
E — evidence strength
62
T1DI (composite)
32
Specificity differential (R−C)+22.3
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 2
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 1
4aPCI-related periproceduralmag 1
4bstent thrombosisn/a
4cin-stent restenosismag 1
5CABG-relatedmag 1
Coverage: 6/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 10 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST)
Method / principle
Immunoturbidimetric/nephelometric
Reagent / substrate
Anti-apoA-I antibody-latex
Platform
Automated analyzer
Turnaround · availability
Routine · Universal

Literature evidence(30)

Clinical trials(1)